Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes
Abstract Background and Aim Sofosbuvir–velpatasvir was recommended for subsidy to treat chronic hepatitis C in Singapore in 2018. We measured the impact of the subsidy decision on clinical practice and patient outcomes. Specifically, we looked at pre‐ and post‐subsidy changes in the utilization and...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | JGH Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jgh3.12850 |